Oncology News

Oncology

sponsor

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Van De Loosdrecht AA et al. - The group also concluded that despite strong evidence for an impact of FCM in myelodysplastic syndromes, further (prospective) validation of markers and immunophenotypic patterns are required against control patient groups as well as further standardization in multi-center studies.

Related Articles

Prognostic molecular markers in myelodysplastic syndromes
Expert Review of Hematology, 10/22/09    Relevance Score: 68%

Hematopoiesis-related microRNA expression in myelodysplastic syndromes
Leukemia and Lymphoma, 11/06/09    Relevance Score: 67%

Clinical significance of Th1/Th2 ratio in patients with myelodysplastic syndrome
International Journal of Laboratory Hematology, 10/28/09    Relevance Score: 66%

Accelerated cellular senescence in myelodysplastic syndrome
Experimental Hematology, 10/22/09    Relevance Score: 66%

Relationship of differential gene expression profiles in CD34+ myelodysplastic syndrome marrow cells to disease subtype and progression
Blood, 10/09/09    Relevance Score: 66%

Today in Myeloproliferative Dz...keeping you current

Inhibitory effect of baicalein on IL-6-mediated signaling cascades in human myeloma cells
European Journal of Haematology, 12/11/09

The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome
Blood, 12/10/09

Solitary Plasmacytoma
American Journal of Clinical Oncology, 12/08/09